Understand the source comparison
SS-LUP-332 News 2026: Comparison With Established Metabolic Peptides
Understanding where SS-LUP-332 fits relative to compounds already in research use clarifies its potential role in metabolic intervention protocols. The table below compares SS-LUP-332 with three established peptides used in metabolic and longevity research. SS
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding where SS-LUP-332 fits relative to compounds already in research use clarifies its potential role in metabolic intervention protocols. The table below compares SS-LUP-332 with three established peptides used in metabolic and longevity research.
- SS-LUP-332
- Dual AMPK activation + mitochondrial biogenesis
- ~4.2 hours (tissue retention 18–22 hours)
- 52% reduction in HOMA-IR in preclinical DIO models; 34% increase in skeletal muscle mitochondrial density
- Phase I trials scheduled Q3 2026
- Best suited for age-related or obesity-driven metabolic dysfunction. Requires baseline impairment to show effect
- Mots C Peptide
- Mitochondrial-derived peptide; enhances glucose metabolism and mitochondrial function
- ~2 hours
- Improved insulin sensitivity and exercise capacity in preclinical models; limited human data
- Research-grade only; no clinical trials registered
- Established mitochondrial modulator with shorter half-life; better studied but narrower mechanism than SS-LUP-332
- Tesofensine
- Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin); thermogenic
- ~8 days
- Mean weight reduction of 9.2% over 24 weeks in Phase II trials (obese adults)
- Completed Phase II; not FDA-approved; available as research compound
- Potent weight loss agent via CNS pathway; different mechanism from SS-LUP-332; longer half-life supports less frequent dosing
- 5 Amino 1MQ
- Inhibits NNMT enzyme; shifts NAD+ metabolism toward fat oxidation
- ~6–8 hours
- Preclinical models show reduction in visceral fat and improved lipid profiles; no published human data
- Research-grade only; no clinical trials
- Targets NAD+ salvage pathway. Complementary to AMPK activation but lacks mitochondrial biogenesis component
- SS-LUP-332 occupies a unique position: it combines mitochondrial structural improvement (like Mots C) with metabolic signaling modulation (like 5 Amino 1MQ) while avoiding CNS mechanisms entirely (unlike Tesofensine). The trade-off is efficacy dependence on baseline metabolic impairment. Healthy populations may not experience measurable benefit.